Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (6ar,10ar)-1-hydroxy-6,6-dimethyl-3-(2-methyl-2-octanyl)-6a,7,8,10a-tetrahydro-6h-benzo(c)chromene-9-carboxylic Acid
2. Ip 751
3. Ip-751
4. Lenabasum
5. Resunab
1. Lenabasum
2. 137945-48-3
3. Resunab
4. Ct-3
5. Ip-751
6. Cpl-7075
7. Ip 751
8. Cpl7075
9. Jbt-101
10. (6ar,10ar)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic Acid
11. Hu-239
12. Lenabasum [usan]
13. Ogn7x90bt8
14. 6h-dibenzo(b,d)pyran-9-carboxylic Acid, 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-, (6ar,10ar)-
15. (6ar,10ar)-3-(1,1-dimethylheptyl)-1-hydroxy-6,6-dimethyl-6a,7,10,10a-tetrahydro-6h-benzo[c]chromene-9-carboxylic Acid
16. Unii-ogn7x90bt8
17. Dmh-thc-11-oic
18. Ab-iii-56
19. Ct 3
20. (6ar,10ar)-3-(1,1-dimethylheptyl)-1-hydroxy-6,6-dimethyl-6a,7,10,10a-tetrahydro-6h-benzo(c)chromene-9-carboxylic Acid
21. Cpl 7075
22. Lenabasum [inn]
23. Lenabasum (usan/inn)
24. Ajulemic Acid [mi]
25. Lenabasum [who-dd]
26. Schembl26441
27. Chembl456341
28. Gtpl9772
29. Dtxsid40900959
30. Ip751
31. 1',1'-dimethylheptyl-delta-8-tetrahydrocannabinol-11-oic Acid
32. Bcp15191
33. Ex-a3627
34. Zinc1905712
35. Bdbm50005920
36. Db12193
37. (6ar,10ar)-1-hydroxy-6,6-dimethyl-3-(2-methyl-2-octanyl)-6a,7,8,10a-tetrahydro-6h-benzo(c)chromene-9-carboxylic Acid
38. 6h-dibenzo(b,d)pyran-9-carboxylic Acid, 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-, (6ar,10ar)
39. Aja
40. Hy-106346
41. Cs-0025624
42. D11312
43. 945a483
44. A935712
45. Q3604498
46. (6ar, 10ar)-3-(1,1-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic Acid
47. (6ar, 10ar)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydro-cannabinol-9-carboxylic Acid
48. 6h-dibenzo(b,d)pyran-9-carboxylic Acid, 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-, (6ar-trans)-
49. Ajulemic Acid; Ct-3; Ip-751; 1',1'-dimethylheptyl-delta8-tetrahydrocannabinol-11-oic Acid
| Molecular Weight | 400.5 g/mol |
|---|---|
| Molecular Formula | C25H36O4 |
| XLogP3 | 7 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 7 |
| Exact Mass | 400.26135963 g/mol |
| Monoisotopic Mass | 400.26135963 g/mol |
| Topological Polar Surface Area | 66.8 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 620 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Cannabinoid Receptor Agonists
Compounds that interact with and stimulate the activity of CANNABINOID RECEPTORS. (See all compounds classified as Cannabinoid Receptor Agonists.)
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Lenabasum manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lenabasum, including repackagers and relabelers. The FDA regulates Lenabasum manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lenabasum API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Lenabasum supplier is an individual or a company that provides Lenabasum active pharmaceutical ingredient (API) or Lenabasum finished formulations upon request. The Lenabasum suppliers may include Lenabasum API manufacturers, exporters, distributors and traders.
Lenabasum Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lenabasum GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lenabasum GMP manufacturer or Lenabasum GMP API supplier for your needs.
A Lenabasum CoA (Certificate of Analysis) is a formal document that attests to Lenabasum's compliance with Lenabasum specifications and serves as a tool for batch-level quality control.
Lenabasum CoA mostly includes findings from lab analyses of a specific batch. For each Lenabasum CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lenabasum may be tested according to a variety of international standards, such as European Pharmacopoeia (Lenabasum EP), Lenabasum JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lenabasum USP).
LOOKING FOR A SUPPLIER?
